DGAP-News: IBU-tec advanced materials AG
/ Key word(s): Miscellaneous
IBU-tec supplies internationally active Asian pharmaceutical group
- Another pharmaceutical company places an order with IBU-tec for a drug to lower blood pressure
- IBU-tec sees further potential for distribution of the organotin catalyst
- More than 1.1 billion people worldwide suffer from high blood pressure
IBU-tec sees further sales and turnover potential for the distribution of the organotin catalyst in the coming years. In recent decades, the number of people suffering from high blood pressure has risen continuously. There are now more than 1.1 billion people suffering from hypertension worldwide, an increasing proportion of whom live in developing and emerging countries.
Ulrich Weitz, CEO of IBU-tec: "Our recent achievements in the pharmaceutical industry fill us with optimism. They also underpin the broad diversification of IBU-tec. After all, battery materials and air purification solutions, for example, are also areas in which we are strong. With our own products for the pharmaceutical industry, we are now tapping into further potential".
The products are important components of battery materials for electric mobility and stationary energy storage, as well as solutions for air purification, resource conservation or the reduction of plastic packaging. IBU-tec is thus in a long-term position to respond to global megatrends, especially in the fields of climate and environmental protection. It has an international customer base ranging from innovative medium-sized companies to global corporations.
Further information can be found online at www.ibu-tec.de.
IBU-tec advanced materials AG
|Company:||IBU-tec advanced materials AG|
|Phone:||+49 (0)3643 - 8649-0|
|Fax:||+49 (0)3643 - 8649-30|
|Listed:||Regulated Unofficial Market in Frankfurt (Scale), Tradegate Exchange|
|EQS News ID:||1082033|
|End of News||DGAP News Service|